Financial Performance - The company's revenue for the first half of 2024 was CNY 2,978,007,248.11, representing a decrease of 18.75% compared to CNY 3,665,297,538.26 in the same period last year[11]. - The net profit attributable to shareholders was CNY 14,155,862.09, down 42.43% from CNY 24,587,865.70 year-on-year[11]. - The net profit after deducting non-recurring gains and losses was CNY 12,741,185.72, a significant decline of 90.20% compared to CNY 130,073,808.09 in the previous year[11]. - The company's operating revenue for the reporting period was ¥2,978,007,248.11, a decrease of 18.75% compared to ¥3,665,297,538.26 in the same period last year[35]. - Operating costs decreased by 20.01% to ¥2,288,312,851.33 from ¥2,860,654,330.55, primarily due to a decline in sales orders[35]. - The net profit for the first half of 2024 was CNY 43,171,412.62, down from CNY 49,316,776.88 in the same period last year, representing a decline of 6.4%[116]. - The total comprehensive income attributable to the parent company was ¥13,831,823.94, a decline of 67.3% from ¥42,182,241.03 in the previous year[117]. Cash Flow and Investments - The net cash flow from operating activities increased by 3.43% to CNY 673,897,924.48 from CNY 651,535,954.21[11]. - The company reported a significant increase in other business revenue by 72.54% to CNY 14,918,004.31[36]. - The net cash flow from investing activities was negative at CNY -372,857,478.98, an improvement from CNY -696,737,283.13 in the first half of 2023[122]. - Cash inflow from financing activities totaled CNY 1,502,081,438.95, down 26% from CNY 2,027,816,973.10 in the same period last year[122]. - The company's cash and cash equivalents at the end of the period increased to CNY 952,896,988.15, compared to CNY 823,907,665.13 at the end of the previous year[122]. Research and Development - Research and development investment fell by 37.15% to ¥139,381,371.76 from ¥221,758,722.90, reflecting a reduction in R&D activities[35]. - The company is actively expanding its research and development capabilities in the pharmaceutical sector, focusing on new technology platforms and clinical pipeline products[19]. - The pharmaceutical R&D team has expanded, developing over 8 continuous process projects in 2024, which significantly reduces costs and safety risks[30]. - The company has established a multi-level R&D platform, including early-stage and mid-stage R&D platforms, to enhance its technological innovation and production efficiency[29]. Business Segments - The company operates in four main business segments: plant protection, pharmaceuticals, functional chemicals, and equipment and engineering services[16]. - The plant protection segment focuses on the production and sales of pesticides and intermediates, with a stable global demand driven by increasing agricultural production needs[17]. - The pharmaceutical segment provides comprehensive CDMO services, supporting global innovative pharmaceutical companies in drug discovery and development, with a focus on enhancing customer relationships and expanding the client base[19]. - The functional chemicals segment is focusing on developing electronic chemicals, battery chemicals, and high-performance polymer materials, aligning with national strategies for battery chemical development and carbon neutrality goals[20]. Environmental Compliance and Sustainability - The company is committed to sustainable development and has invested in environmental protection and safety production measures[52]. - The company has maintained zero exceedances in all reported emissions across its facilities[64][65]. - The company achieved a CDP rating of B in 2023, marking a significant improvement in its climate change management efforts[73]. - The company has established a comprehensive greenhouse gas emission management system to promote sustainable development and minimize climate impact[73]. Corporate Governance - The management team guarantees the financial report's authenticity, accuracy, and completeness[1]. - All board members attended the meeting to review the semi-annual report[1]. - The company held its first extraordinary general meeting of 2024 on April 10, with an investor participation rate of 28.60%[59]. - The company has established a comprehensive internal control system to enhance operational efficiency across its geographically dispersed factories[56]. Risks and Challenges - The company faced risks from macroeconomic fluctuations, which could impact business operations and market demand, leading to reduced customer demand and sales[51]. - Environmental safety risks were highlighted due to the nature of the chemical industry, with potential increased costs to meet higher environmental standards impacting operational performance[52]. - The company is addressing raw material price volatility risks by enhancing supply chain management and reducing reliance on single raw materials, while also implementing strict supplier management[53]. Shareholder Information - The company plans not to distribute cash dividends, issue bonus shares, or increase capital from reserves[1]. - The company completed a share buyback of 11,913,139 shares, accounting for 1.29% of the total share capital, with a total expenditure of approximately RMB 79.82 million[95]. - The largest shareholder, Mou Jinxiang, holds 25.40% of the total shares, amounting to 234,535,853 shares[98]. - The company has a total of 32,765 common shareholders at the end of the reporting period[98].

单位：万元 | | 资金占用方名称 | 占用方与上市公司 | 上市公司核算 | 2023 年期初占用资 | 2023 | 年半年度占用累 计发生金额（不含利 | 2023 年半年度 占用资金的利息 | 2023 年半年度 偿还累计发生 | 2023 年期末占 | 占用形成原因 | 占用性质 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | | 的关联关系 | 的会计科目 | 金余额 | | | | | 用资金余额 | | | | | | | | | | | 息） | (如有) | 金额 | | | | | | 控股股东、实际控制人及其附属 | | | | | | | | | | | 非经营性占用 | | | 企业 | | | | | | | | | | | 非经营性占用 | | | 小计 | - | - | - | | | | | | | - | - | | | 前控股股东、实际控制人及其附 | | | | | | | | | | | 非经营性占用 | | | 属企业 ...

证券代码：002250 证券简称：联化科技 公告编号：2024-039 联化科技股份有限公司（以下简称"公司"）于2024年5月22日召开的2023年 度股东大会审议通过了《关于变更公司经营范围及修订公司章程与其附件的议 案》。 近日，公司办理了工商变更登记及《公司章程》备案手续，并取得了浙江省 市场监督管理局换发的《营业执照》，变更后情况如下： 经营范围：一般项目：技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广；货物进出口；技术进出口；基础化学原料制造（不含危险化学品 等许可类化学品的制造）；专用化学产品制造（不含危险化学品）；专用化学产品 销售（不含危险化学品）；化工产品生产（不含许可类化工产品）；化工产品销售 （不含许可类化工产品）；生物化工产品技术研发；电子专用材料制造；电子专 用材料销售；电子专用材料研发(除依法须经批准的项目外，凭营业执照依法自 主开展经营活动)。许可项目：危险化学品生产；新化学物质生产；房地产开发经 营(依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目 以审批结果为准)。 其他登记项未发生变更。 联化科技股份有限公司 关于公司完成工商变更登记的公告 ...

证券代码：002250 证券简称：联化科技 公告编号：2024-038 联化科技股份有限公司 2023 年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、根据《中华人民共和国公司法》（以下简称"《公司法》"）的规定，联化 科技股份有限公司（以下简称"公司"）回购专用证券账户持有的11,913,139股不 享有参与本次权益分派的权利。本次权益分派方案为：以公司现有总股本剔除已 回购股份11,913,139股后的911,333,117股为基数，向全体股东每10股派0.20元(含 税)。 2、根据2023年度权益分派方案，公司本次实际现金分红的总金额=实际参与 分配的总股本×分配比例，即18,226,662.34元=911,333,117股/10×0.20元/股。因 公司回购专用证券账户所持股份不参与现金分红，本次权益分派实施后，根据股 票市值不变原则，实施权益分派前后公司总股本保持不变，现金分红总额分摊到 每一股的比例将减小，因此，本次权益分派实施后除权除息价格计算时，每股现 金红利应以0.0197419元/股计算（每股现金红利 ...

三、风险提示 关于控股子公司申请新三板挂牌的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基本情况 联化科技股份有限公司（以下简称"联化科技"或"公司"）于2024年6月14 日召开了第八届董事会第十六次会议，审议通过了《关于控股子公司拟申请在新 三板挂牌的议案》，同意公司控股子公司上海宝丰机械制造股份有限公司（以下 简称"上海宝丰"）拟申请在全国中小企业股份转让系统（以下简称"新三板"） 公开转让并挂牌事宜，并授权公司及上海宝丰管理层具体办理上海宝丰新三板挂 牌相关事宜。上述事项详见公司2023年6月15日刊登于《证券时报》、《上海证券 报》和巨潮资讯网（www.cninfo.com.cn）的《第八届董事会第十六次会议决议公 告》（公告编号：2024-035）和《关于控股子公司拟申请在新三板挂牌的公告》（公 告编号：2024-036）。 二、进展情况 上海宝丰于近日收到全国中小企业股份转让系统有限责任公司出具的《受理 通知书》（文号：GP2024060059）。上海宝丰报送的在全国中小企业股份转让系统 挂牌的申请材料，经审查符合《非上市公众公 ...

联化科技股份有限公司 第八届董事会独立董事专门会议第一次会议决议 独立董事对公司第八届董事会第十六次会议审议的相关议案进行了预审议， 经过审慎分析，基于独立判断，形成以下决议： 一、会议以3票同意，0票反对，0票弃权的表决结果，审议并通过《关于控 股子公司拟申请在新三板挂牌的议案》。 经核查，公司控股子公司上海宝丰申请在新三板挂牌，有利于上海宝丰进一 步完善其法人治理结构，拓宽资本渠道，帮助其业务整合与发展，同时也有利于 上市公司总体经营战略的实施，不存在损害股东和公司利益的情况，不会影响公 司独立上市地位，也不会对公司的持续经营运作产生重大影响。我们同意公司控 股子公司上海宝丰在符合国家相关法律法规政策和各项条件成熟的情况下申请 在新三板挂牌，并提交公司董事会审议。 独立董事：蒋萌、俞寿云、Zhang Yun 2024年6月14日 联化科技股份有限公司第八届董事会独立董事专门会议第一次会议通知于 2024 年 6 月 11 日以电子邮件的方式发出，于 2024 年 6 月 14 日 8 时在本公司会 议室以通讯表决的方式召开，应出席会议独立董事3名，实际出席独立董事3名。 会议的召开符合《中华人民共和国公司 ...

证券代码：002250 证券简称：联化科技 公告编号：2024-036 联化科技股份有限公司 关于控股子公司拟申请在新三板挂牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"联化科技"或"公司"）于2024年6月14 日召开了第八届董事会第十六次会议，审议通过了《关于控股子公司拟申请在新 三板挂牌的议案》，同意公司控股子公司上海宝丰机械制造股份有限公司（以下 简称"上海宝丰"）拟申请在全国中小企业股份转让系统（以下简称"新三板"） 公开转让并挂牌事宜，并授权公司及上海宝丰管理层具体办理上海宝丰新三板挂 牌相关事宜。该议案无需提交公司股东大会审议。现将有关事项公告如下： 一、上海宝丰基本情况 （一）工商登记情况 公司名称：上海宝丰机械制造股份有限公司 公司类型：股份有限公司(非上市、自然人投资或控股) 统一社会信用代码：91310113734085795W 公司住所：上海市宝山区工业路 458 号 法定代表人：彭寅生 注册资本：14,129.8420 万元人民币 成立时间：2001 年 12 月 17 日 与公司的关系：为 ...

证券代码：002250 证券简称：联化科技 公告编号：2024-035 联化科技股份有限公司 第八届董事会第十六次会议决议公告 一、会议以4票同意，0票反对，0票弃权的表决结果，审议并通过《关于控 股子公司拟申请在新三板挂牌的议案》，关联董事彭寅生先生、何春先生、樊小 彬先生回避表决。 公司董事会同意公司控股子公司上海宝丰机械制造股份有限公司（以下简称 "上海宝丰"）拟申请在全国中小企业股份转让系统（以下简称"新三板"）公开 转让并挂牌事宜，并授权公司及上海宝丰管理层具体办理上海宝丰新三板挂牌相 关事宜。 具体详见公司同日刊登于《证券时报》、《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）的《关于控股子公司拟申请在新三板挂牌的公告》（公告 编号：2024-036）。 特此公告。 联化科技股份有限公司董事会 二〇二四年六月十五日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 联化科技股份有限公司（以下简称"公司"）第八届董事会第十六次会议通 知于2024年6月11日以电子邮件方式发出。会议于2024年6月14日在联化科技会议 室以现场与通讯表 ...

Group 1: Financial Performance - The company's Q1 2023 and Q1 2024 performance was poor, primarily due to the "de-inventory" trend in the plant protection industry, leading to a reduction in orders and revenue decline [1] - The company expects the "de-inventory" trend to slow down in the second half of the year, with a recovery in patented products compared to generic products [1] - The company is actively communicating with clients to maintain strategic relationships and mitigate the impact of "de-inventory" [1] Group 2: Business Development - The company has established a CRO team to enhance customer service and increase client retention, with the CRO business progressing as planned [2] - In the renewable energy sector, the company is conducting R&D and pilot production, aiming to leverage its chemical industry experience for future success [2] - The UK subsidiary is undergoing production line modifications and is actively seeking new clients and products to drive growth [2] Group 3: International Expansion - The company has signed a purchase intention for industrial land in Malaysia and is adjusting the construction schedule based on specific orders [2] - The Malaysian factory and UK subsidiary will work together to enhance international competitiveness and support the "going out" strategy [2] Group 4: ESG Initiatives - The company is implementing ESG measures, particularly in its pharmaceutical subsidiary, which includes carbon emission management [3] - Future ESG efforts will be promoted company-wide based on existing experiences and results, with targeted disclosures to meet regulatory and stakeholder needs [3]

Financial Performance - In 2023, the company achieved an operating revenue of 644,215.28 thousand yuan, a decrease of 18.10% compared to the previous year [1] - The industrial business revenue was 641,015.50 thousand yuan, down 18.41% year-on-year [1] - The total profit was -40,205.38 thousand yuan, a decline of 142.57% compared to the previous year [1] - The net profit attributable to shareholders was -46,524.39 thousand yuan, a decrease of 166.76% year-on-year [1] - In Q1 2024, the company reported an operating revenue of 146,559.74 thousand yuan, down 25.12% year-on-year [1] - The net profit attributable to shareholders in Q1 2024 was 269.16 thousand yuan, a decrease of 93.96% compared to the same period last year [1] Asset Management and Strategy - The company is actively working to optimize asset utilization due to increased asset size and management challenges [2] - Strategies include rapid switching of production lines in multi-functional workshops and the "going out" strategy focusing on the UK and Malaysia [2] - The company aims to enhance domestic base development through external orders while maintaining high-quality sustainable growth [2] Industry Trends - The company anticipates a slowdown in the "de-inventory" trend in the agricultural protection industry in the second half of the year [2] - The recovery of patented products is expected to outpace that of generic drugs, which will be reflected in next year's financial statements [2] International Operations - The UK subsidiary faced losses in 2023 due to internal loan interest and low capacity utilization from the "de-inventory" trend [2] - The company is reviewing the UK operations to improve management and will adjust product offerings to enhance local production efficiency [2] Competitive Landscape - The company is preparing for challenges post-patent expiration by developing new technologies and optimizing production processes [3] - It believes that China's comprehensive supply chain and waste management systems provide a competitive edge against Indian competitors [3] Pharmaceutical and New Energy Business - The pharmaceutical segment is expanding its client base and enhancing R&D capabilities, having passed FDA and PMDA audits in 2023 [3] - New energy products like lithium hexafluorophosphate and lithium bis(fluorosulfonyl)imide are in trial production, with a focus on optimizing processes to reduce costs [3]